Neurocrine Biosciences, Inc. NBIX
NASDAQ
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 3.70B | 3.37B | 3.10B | 2.86B | 2.68B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 3.70B | 3.37B | 3.10B | 2.86B | 2.68B |
| Cost of Revenue | 1.30B | 1.20B | 1.10B | 1.07B | 984.90M |
| Gross Profit | 2.40B | 2.18B | 2.00B | 1.79B | 1.70B |
| SG&A Expenses | 1.36B | 1.30B | 1.20B | 1.16B | 1.14B |
| Depreciation & Amortization | 51.40M | 17.40M | 2.00M | 2.00M | 2.00M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 2.72B | 2.51B | 2.30B | 2.22B | 2.13B |
| Operating Income | 985.00M | 865.30M | 798.10M | 635.80M | 553.60M |
| Income Before Tax | 932.10M | 940.20M | 937.50M | 705.40M | 628.60M |
| Income Tax Expenses | 229.60M | 234.70M | 268.90M | 226.80M | 200.60M |
| Earnings from Continuing Operations | 702.50 | 705.50 | 668.60 | 478.60 | 428.00 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 702.50M | 705.50M | 668.60M | 478.60M | 428.00M |
| EBIT | 985.00M | 865.30M | 798.10M | 635.80M | 553.60M |
| EBITDA | 1.07B | 912.60M | 827.90M | 665.90M | 583.30M |
| EPS Basic | 6.97 | 7.05 | 6.70 | 4.81 | 4.30 |
| Normalized Basic EPS | 6.53 | 5.93 | 5.61 | 4.56 | 4.02 |
| EPS Diluted | 6.74 | 6.82 | 6.49 | 4.66 | 4.18 |
| Normalized Diluted EPS | 6.31 | 5.75 | 5.44 | 4.42 | 3.92 |
| Average Basic Shares Outstanding | 403.00M | 400.80M | 398.80M | 398.00M | 398.10M |
| Average Diluted Shares Outstanding | 416.50M | 413.80M | 410.60M | 409.70M | 408.90M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |